Enterprise Solutions

INSIGHTS ON ENTERPRISE SOLUTIONS

Self-Amplifying RNA: The Next Chapter In mRNA Therapeutics
Self-amplifying RNA builds on mRNA technology by enabling intracellular replication, delivering stronger and longer-lasting responses at lower doses while improving scalability, cost-efficiency, and global accessibility.
Every Milliliter Matters: Maximizing Yield In Fill-Finish
A technical overview of minimizing product loss in aseptic fill‑finish processes, highlighting key loss points and practical strategies to improve yield, efficiency, and manufacturing consistency.
India's Only GLP-Certified Viral Testing Facility
Get an overview of a GLP-certified viral testing facility that delivers comprehensive safety solutions, collaborative research support, and viral clearance data for biologics processes.
Faster Clones, Simpler Process: What's Changing In CHO Expression?
This presentation examines how enhanced glutamine synthetase selection stringency, combined with a high-strength gene promoter, provides greater control over gene expression and supports CHO cell line development.

What Can Our Global CRO/CDMO Services Do For You?
6/3/2026

Explore the state-of-the-art multi-product, multi-client contract manufacturing facility that could serve as your one-stop shop for drug discovery, development, and manufacturing needs.
Smarter By The Second Redefining Pharma Biopharma Manufacturing
6/2/2026

Continuous monitoring is transforming manufacturing. With advanced analytics and sensor technologies, teams can detect issues early and optimize processes in real time for greater efficiency.
The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry
6/2/2026

In this special edition of “Better Biopharma,” host Tyler Menichiello is joined by chief editors from across the Life Science Connect ecosystem to discuss what’s shaping the pharmaceutical industry in 2026. The editors reflect on recent developments in their respective spaces and make predictions on what the rest of the year has in store.
End-To-End Process Scalability Of HEK 293 Media For High Titer AAV Production
6/2/2026

Explore how controlled bioreactor environments enable optimization of critical process parameters and support robust, scalable AAV production from development through manufacturing.

AAV Production Technology For Scalable, High-Quality Manufacturing

Plasmid-free AAV production technology enhances yield, purity, and scalability, enabling cost-efficient manufacturing, reduced variability, and consistent high-quality vectors for gene therapy.
Lentiviral Packaging & Producer Cell Lines For LVV Manufacturing

Stable lentiviral vector line platforms enable scalable, cost-efficient manufacturing by reducing plasmids, simplifying processes, improving consistency, and supporting volume production.
20% Ethanol With WFI In Single Use Bags

Formulated to 19.0%–21.0% v/v from USP-grade components, this ready-to-use ethanol solution ships in IPEC/ISO 9001-compliant single-use bags with aseptic dispensing and direct sampling connections built in.
Madison: Clinical, Commercial Drug Substance Development

Catalent Madison offers gene-to-GMP drug substance in 8 months via GPEx Lightning CHO cell lines, hitting 15+ g/L, backed by 24 approved products and 5 GMP trains up to 4,000 L.
We Navigate You Through Drug Development

Bringing complex therapies to market requires seamless integration across development, manufacturing, and regulatory strategy to reduce risk, speed timelines, and ensure quality.